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Background/aim: Hashimoto thyroiditis (HT) is one of the most prevalent autoimmune diseases. The intestine microbiota is strongly
associated with autoimmune diseases. Zonulin, a modulator of tight junctions that controls the selective permeability of the intestine
can induce an elevation in gut permeability. We aimed to investigate the association of plasma zonulin levels with HT.
Materials and methods: We compared 77 HT patients with 66 age-gender and BMI-matched healthy individuals in the case of plasma
zonulin levels. Plasma zonulin levels were measured by ELISA. The statistical analyses were performed using Student’s t-test and chisquare tests. The predictive power was investigated using univariate and multivariate logistic regression analysis.
Results: We found that the increase in plasma zonulin levels in the HT group was statistically significant compared to the control
group (p < 0.001). The regression analysis showed that urea, anti-thyroid peroxidase, aspartate aminotransferase, thyroid-stimulating
hormone, free T3, and serum zonulin levels were found to be associated with HT in both univariate and multivariate models (p < 0.05).
Conclusion: Zonulin is a possible biomarker candidate that may link intestinal permeability with the etiology of autoimmune diseases.
Key words: Hashimoto thyroiditis, autoimmune diseases, microbiota, gut permeability, zonulin

1. Introduction
The first serious description and analyses of autoimmune
thyroiditis leading to primary hypothyroidism emerged
during the 1910s [1]. Hakaru Hashimoto, in 1912,
defined a distinctive hypothyroidism disease in which
inflammatory cells infiltrate into thyroid tissue resulting
in the production of antibodies against thyroid hormones
such as triiodothyronine (T3) and thyroxine (T4) which are
synthesized by a pivotal enzyme, namely thyroperoxidase
(TPO) [2]. Generally speaking, commonly observed in
females (>15% of +60 years females but <2% of males)
[3], this disease is a major public health problem which
corresponds to 10% of all adult hypothyroiditis patients
[4] and is called “Hashimoto’s thyroiditis (HT)” after being
discovered. The disease displays its symptoms via the
elevation of antibodies (anti-TPO) against enzyme TPO
which is observed in nearly 20% of general society and
almost always increases in HT [5].
The intestinal epithelium, composed of single-layered
epithelial cells lining the small intestine, provides the

largest mucosal barrier between the external environment
and the human host [6]. The selectively regulated passage
of macromolecules is maintained by intestinal paracellular
permeability which depends on the integrity of one
of the hallmarks of absorptive and secretory epithelia,
intercellular tight junctions (TJs) [7]. TJs are highly
dynamic structures capable of rapid and coordinated
responses that separate the basolateral and apical cellular
compartments. In healthy conditions, quantitively small
macromolecules with active immunogenicity are allowed
to cross the mucosal barrier [8].
The intestinal microbiota displays a substantial function
to maintain the homeostasis of the gastrointestinal system
and may be at the heart of our understanding of thyroid
disorders [9]. Intestinal flora teeming with various
microbial organisms may explain the large differences
among different world regions in the prevalence of goiter,
a thyroid disorder mainly caused by insufficient iodine
(I-) intake. For example, in southern India, goiter is not
associated with I- intake, whereas hypothyroidism is more
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common in iodine-rich areas of Japan than in iodine-poor
areas [10,11].
The end products of intestinal microbiota such as
short-chain fatty acids are reservoirs of energy to be served
in the production of thyroid hormones and strengthening
intercellular TJs [12]. The cooperation of intestinal content
and intercellular TJs stabilizes homeostasis in case of the
immune response to nonself antigens thus the presence
of an aberrant intestinal gut microbiome triggers the
proliferation of auto-reactive T-cells [13].
Considering the possible external inducers of HT, the
gut emerges as a key region, as the immune system
with mucosa experiences and responds to the outside
environment for the first time. Many autoimmune diseases
such as diabetes, inflammatory bowel disease (IBD), and
neurodegenerative diseases, cardiovascular diseases
and cancers are being associated with microbiota [14],
while several ones with the aberrant intestinal barrier
permeability [15].
Zonulin is a paracrine signaling protein largely
secreted by small intestine epithelial cells that coordinate
the opening of intestinal TJs [16]. In normal antigenic
trafficking within the small intestine, TJs’ main component,
zonula occludens 1 (ZO-1) form the TJs complex with the
help of actin filaments binding. However, zonulin binding
to two transmembrane receptors, namely proteaseactivated receptor 2 and epidermal growth factor receptor
triggers a cascade in which phospholipase C activates
protein kinase C alpha, which in turn catalyzes the
phosphorylation of ZO-1 and other target proteins and the
depolymerization of actins [17] which eventually results in
a loose conformation of TJs, increased permeability, and
excessive-abnormal antigenic trafficking (Figure 1).
Based on the relationship between the intestinal
microbiome, intestinal permeability, and autoimmunity,

we sought to explore whether elevated levels of plasma
zonulin contributed to HT. Here, we discuss the crosstalk
between plasma zonulin levels and HT susceptibility,
which may improve target-specific therapy for HT.
2. Materials and methods
2.1. Study subjects
The study enrolled newly diagnosed 77 Hashimoto
thyroiditis patients (75 of females and 2 of males) and agegender-BMI matched 66 healthy subjects (65 of females
and 1 of male) at the Internal Medicine Department
outpatient clinic of Kanuni Sultan Süleyman Traning and
Research Hospital, İstanbul, Turkey.
Generally speaking, the individuals with an increased
thyroid-stimulating hormone (TSH) and low levels of free
thyroxine (FT4), with elevated antithyroid peroxidase
(TPO) antibodies demonstration coupled with the physical
examination and differential diagnosis from many other
thyroid gland related disorders or autoimmune diseases
are included within the study as the patients’ group [18].
Individuals with no systemic or autoimmune disease
history are included as the control group. The mean age
was 36.8 ± 9.3 years in the patients and 34.6 ± 11.4 in
control groups. All procedures were performed following
the ethical standards of the Institutional Ethics Committee
of our hospital (Ethics Committee decision no: KAEK2019.04.87) and with the 1964 Helsinki Declaration ethical
standards. All study subjects were inhabitants of İstanbul
having Turkish origin and provided signed informed
consent prior to the sample and data collection.
2.2. Sample preparation
After the patient or the control had fasted for at least 8 h,
peripheral blood samples were taken from antecubital veins
in the morning, thereafter, samples were collected in tubes

Figure-1

Figure 1. ZO-1 is the main part of the TJs. A. During normal antigen trafficking, ZO-1 is strictly bound to TJs complex with the help of
actin filaments leading to selectively permeability of the intestinal barrier. B. In the presence of zonulin, the activated EGFR and PAR2
receptors trigger phospholipase C activation which in turn activates PKC-α. Activated PKC-α then triggers the release of ZO-1 and actin
filaments leading to dysfunction of TJs and aberrant barrier permeability. PAR2: protease-activated receptor 2, PKC-α: Protein Kinase C
Alpha, ZO-1: Zona Occludens 1, EGFR: Epidermal growth factor receptor (the figure was drawn using biorender.com).
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with EDTA for biochemical analysis and without additives
for serum zonulin level. The following parameters were
run simultaneously. In biochemical analysis, complete
blood count, liver function parameters such as gammaglutamyltransferase (GGT), alanine aminotransferase
(ALT) and aspartate aminotransferase (AST), potassium
and sodium levels, fasting blood glucose, HbA1c,
thyroid-stimulating hormone, free T3, free T4, antithyroid peroxidase, triglyceride, high-density lipoprotein
cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), total cholesterol, urea, uric acid, and creatinine
were measured. An Abbot Aeroset 2.0 (Abbot Diagnostic,
USA) was used for spectrophotometric calculation of the
amount of liver enzymes ALT, AST, and GGT, lipid profiles,
uric acid and glucose levels, whereas Sysmex XN 9000
hematology analyzer (Symex Europe GmbH, Germany)
was for the complete blood count, Cobas 8000 C702
(Roche Diagnostics, USA) chemistry analyzer was for
Na and K electrolytes and Variant 2 Turbo (Biorad, USA)
was for HbA1c%. Plasma zonulin concentrations were
determined by an enzyme-linked immunosorbent assay
(Human Zonulin ELISA kit, Cat no: E3704Hu, Bioassay
Technology Laboratory, Shanghai, CHINA). The intraassay precision of the kit is <8%, whereas the interassay
precision is <10%. The precision (%) is calculated by the
equation of SD/mean x 100.
2.3. Statistical analysis
In the descriptive statistics of the data, the median,
standard deviation, average, frequency, lowest-highest
values, and ratio were determined. The distribution of
variables was measured by the Kolmogorov Smirnov test.
In the analysis of quantitative independent data, normal
distribution between groups was evaluated using Student’s
t-test, while the Mann–Whitney U test was used for
nonnormally distributed data. The qualitative independent
data were evaluated by the chi-square test. In the cases the

chi-square test conditions were not met, the Fischer test
was applied. The predictive power was investigated using
univariate and multivariate logistic regression analysis.
The predictive power and cut-off value were analyzed with
the ROC curve. The Statistical Package for Social Sciences
statistical software release 22 (IBM Corporation, Armonk,
NY) was used for the statistical calculations.
3. Results
The demographics, laboratory parameters and clinical
features of both control and HT patients are summarized
in Table 1 and Table 2.
There was no significant difference between the
Hashimoto thyroiditis and control groups concerning age,
gender, height, weight, and body mass index (p > 0.05) for
all comparisons (Table 1).
The fasting glucose, total cholesterol, LDL, HDL, uric
acid, creatinine, TG, HgA1c, ALT, GGT, Na, K, FT4, WBC,
PLT, MPV, and Hgb levels were not significant statistically
between the patient and control groups. The level of ure (p
= 0.010), anti-TPO (p ≤ 0.001), AST (p = 0.005), TSH (p
≤ 0.001), and serum zonulin (p≤0.001) (Figure 2) elevated
significantly whereas the FT3 level decreased (p = 0.008)
in patient groups compared to control group (Table 2).
Uni/multivariate regression analysis was performed to
determine the possible influence of urea, anti-TPO, AST,
TSH, FT3, and serum zonulin on the presence of HT. Urea,
anti-TPO, AST, TSH, FT3, tri-iodothyronine, and serum
zonulin levels were found to be associated with HT in both
univariate and multivariate models (p < 0.05) (Table 3).
To determine the predictive power of plasma zonulin
levels in the case of HT, a ROC analysis was performed
(Figure 3-A,B) (Table 4). The plasma zonulin level of ≥4
ng/mL had a sensitivity (100%) so the positive predictive
value (PPV) of 100% whereas a specificity (90.6%) so the
negative predictive value (NPV) of 90.9% (Table 4). In
the discrimination of the patient and control group, we

Table 1. The comparison of demographic characteristics between Hashimoto’s thyroiditis and control
groups.

Parameters
Age, years
Gender

Control group

Thyroiditis group

Mean ± SD/n-%

Mean ± SD/n-%

34.6
Female

65

Male

1

±

11.4

36.8

98.5 %

75

±

p
9.3

0.202

97.4%

1.000

1.5 %

2

2.6%

1.000

Height, m

1.6

±

0.0

1.6

±

0.1

0.717

Weight, kg

66.3

±

13.4

69.1

±

13.6

0.316

BMI; kg/m2

25.0

±

4.9

25.9

±

5.0

0.352

BMI, Body mass index; s.d, Standard deviation; m, Meter; n, Number; m2, Square meter; kg, Kilogram

607

DEMİR et al. / Turk J Med Sci
Table 2. The comparison of laboratory parameters between Hashimoto’s thyroiditis and control groups.

Parameters

Control group
Mean ± SD

Thyroiditis group
Median

Mean ± SD

p

Median

Glucose, mg/dL

88.7

±

8.5

91.2

±

9.5

Urea, mg/dL

22.9

±

7.2 22

27.8

±

24.3

Creatinine, mg/dL

0.6

±

0.1

0.6

±

0.1

AST, U/L

15.5

±

2.6

18.0

±

7.8

ALT, U/L

14.8

±

4.9

16.8

±

11.0

LDL, mg/dL

92.5

±

28.5

101.4

±

38.5

0.186

HDL, mg/dL

59.5

±

14.6

56.4

±

11.5

0.335

TG, mg/dL

86.7

±

49.7

92.1

±

44.3

0.371

T. Chol, mg /dL

168.3

±

35.0

174.9

±

45.1

0.579

Uric acid, mg/dL

3.7

±

0.9

3.8

±

0.9

0.481

GGT, U/L

12.9

±

5.2

14.8

±

15.7

Hb, g/dL

12.6

±

1.3

12.3

±

1.5

0.338

WBC, (×10 )

7.2

±

1.9

7.1

±

1.6

0.934

Platelets (×109)

269.5

±

63.4

278.5

±

55.6

0.382

MPV, fL

10.8

±

0.9

11.3

±

7.5

0.092

Sodium, mmol /L

140.7

±

2.0

140.3

±

1.5

0.381

Potassium, mmol /L

4.4

±

0.3

4.5

±

0.4

0.051

HbA1c, g/dL

5.2

±

0.4

5.3

±

0.4

0.358

TSH, uIU/mL

2.0

±

1.3

4.9

±

11.3

FT3, pg/mL

3.2

±

0.5

3.0

±

0.5

0.008

FT4, ng / dL

1.3

±

0.7

1.2

±

0.5

0.935

ANTI-TPO, IU/mL

11.9

±

5.0

259.5

±

179.0

≤0.001

Zonulin, ng/mL

6.4

±

1.9

7.7

±

1.5

≤0.001

3

14

11

1.6

0.111
25

0.010
0.367
0.005

14

11

3.3

0.498

0.887

≤0.001

HbA1C, Hemoglobin A1C; TG, Triglyceride; AST, Aspartate aminotransferase; LDL, Low-density lipoprotein;
HDL, High-density lipoprotein; T. Chol, Total cholesterol; Hb, Hemoglobin; ALT, Alanine aminotransferase; GGT,
Gamma-glutamyl transferase; WBC; White blood counts, MPV; Mean platelets volume; FT4, Free thyroxine; FT3,
Free triiodothyronine; TSH, Thyroid stimulating hormone; ANTI-TPO, Anti-thyroid peroxidase; mg, Milligram; U,
Unit; s.d, Standard deviation; L, Liter; n, Number; dL, Deciliter; g, Gram; fL, Femtoliter; mmol, Milimol; mL, Milliliter;
pg, Picogram; ng, Nanogram.

observed a statistically significant efficiency of plasma
zonulin levels [area under the curve 0.705 (0.617–0.792)]
(Figure 3-B).
4. Discussion
The most important result of our study is that plasma
zonulin levels were higher in the HT group than in the
control group. In this context, zonulin as a marker of
impaired intestinal permeability may play a role in the
pathogenesis of autoimmune diseases.
Humans come to earth from a sterile nature fulfilled
with amniotic fluids and afterward the surfaces layered
by epithelia such as skin, genital, nasal, and respiratory
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system tracts are covered systemically by microorganisms
[19]. For human survival, it is mandatory to maintain
tissue homeostasis. The homeostasis is balanced by the
interaction between the host and the microorganisms
living inside it. This is the code for a multicellular
organism’s existence as both the symbiotic commensal
microbiota inside the host and the macroscopic host
are the two sides of the same coin. This substantial task
is succeeded by a complex but coordinated set of both
adaptive and innate reactions that modulate responses
optimally against nutrients, commensal microorganisms,
and probable pathogens [20]. Although the breakthrough
in understanding the role of microbiota in the gut was Do
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Figure 2. The comparison of zonulin levels between control and patient groups.

connected to autoimmune diseases. Generally speaking,
patients having autoimmunity disorders represent proof
of aberrant gut barriers which in turn lead to an immune
response to commensal gut bacteria [7].
There is a growing body of evidence regarding the
microbiota and its possible role in the autoimmune
response. As reported in the Mu survey, a significant
alteration in gut microbiota is found between susceptible,
healthy or resistant samples in the case of collageninduced arthritis murine model [22]. Several autoimmune
diseases such as systemic lupus erythematosus [23],
inflammatory bowel disease [24], systemic sclerosis [25],
rheumatoid arthritis [26], type 1 diabetes (T1D) [27]
and spondyloarthritis [28] are linked to gut microbiota
alteration.
Zonulin, as the key to forcing the intestinal barrier
to be more permeable, manages TJs regulation so the
reciprocal movement of macromolecules, fluid, and the
leukocytes [15].
This research examines the emerging role of the
plasma zonulin levels in the context of an autoimmune
disease, namely Hashimoto’s thyroiditis. Increased plasma
zonulin levels may allow pathogenic antigens to pass the
intestinal gut barrier loosening the TJs which can explain
the auto-response of innate immunity. Our findings are
in agreement with other autoimmune diseases, as plasma
zonulin concentrations elevated in celiac disease [17], T1D
[29], and inﬂammatory bowel disease such as Crohn’s
disease and ulcerative colitis [30].
Without a shadow of doubt, the discovery of zonulin
which is the only physiological gut permeability regulator
depicted so far has been the breakpoint to understand
the role of intestinal permeability in both disease and
health. This study was the first to represent the association
between HT and plasma zonulin levels.

Serum Zonulin Levels
14
12
10
8
6
4
2
0

ng /mL

Control Group

Patient Group

Figure 2. The comparison of plasma zonulin levels between
control and patient groups.

derlein’s work which reported a specific bacteria type as
the gate-keeper of the vaginal ecosystem in 1892, more
than two thousand years ago, Hippocrates the father of
medicine, claimed that all disease begins in the gut.
Autoimmune disorders are described as self-tissue
damage presence in diverse regions of the human body.
Innate cells, circulating autoantibodies, and eventually
autoreactive lymphocytes are the three arms of the
inflammation, however, the mechanisms responsible for
the triggering and maintaining the process remain to be
figured out completely. Gut commensal microorganisms
as being the target of the adaptive immune system display
a connective role in homeostasis [21]. Thus, any alteration
in the population of these microorganisms is directly

Table 3. The regression analysis of univariate and multivariate models within the patient group.
Univariate model

Multivariate model

OR

95% CI

p

OR

95% CI

Urea

1.05

1.01

-

1.10

0.047

Anti-TPO

1.49

1.06

-

2.08

AST

1.16

1.04

-

1.29

TSH

1.62

1.29

-

FT3

0.42

0.21

-

Serum Zonulin

1.58

1.26

-

p

0.022

1.21

1.07

-

1.36

0.002

0.007

1.21

1.07

-

1.36

0.002

2.04

≤0.001

1.62

1.25

-

2.11

≤ 0.001

0.86

0.017

0.35

0.15

-

0.81

0.015

1.98

≤ 0.001

1.55

1.21

-

2.00

≤ 0.001

OR: Odds ratio, Cl: Confidence interval
ANTI-TPO, Anti–thyroid peroxidase; AST, Aspartate aminotransferase; TSH, Thyroid stimulating hormone; FT3, Free
triiodothyronine
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Figure 3. A-The diagrammatic illustration of serum zonulin predictive power in case of
sensitivity and specificity. B-The efficiency of zonulin levels is found statistically significant
DEMİR et al. / Turk J Med Sci
[area under the curve 0.705 (0.617-0.792)].

Serum Zonulin Predictive Power

A

100,0%
80,0%
60,0%
40,0%
20,0%
0,0%

1,0 2,0 3,0 4,0 5,0 6,0 7,0 8,0 9,0 10,0 11,0 12,0 13,0
Sensitivity

Specificity

B

Figure 3. A-The diagrammatic illustration of serum zonulin predictive power in case of sensitivity and specificity. B-The
efficiency of plasma zonulin levels is found statistically significant [area under the curve 0.705 (0.617–0.792)].
Table 4. The sensitivity and specificity of different cut-off values
of plasma zonulin levels.
Zonulin

Sensitivity

Specifity

1.0

100.0%

100.0%

2.0

100.0%

98.5%

3.0

100.0%

97.0%

4.0

100.0%

90.9%

5.0

96.1%

72.7%

6.0

88.3%

59.1%

7.0

66.2%

36.4%

8.0

39.0%

21.2%

9.0

15.6%

9.1%

10.0

6.5%

3.0%

11.0

2.6%

0.0%

12.0

1.3%

0.0%

13.0

0.0%

0.0%

The zonulin may be used as a marker in the future
to predict clinical response in HT. The small sample size,
absence of power analysis before the study, and the lack of
additional markers that can affect the gut permeability and
the nutritional status that can alter plasma zonulin levels
measured are the limiting factors of our study. Additional
work with larger sample size is needed not only to confirm
our results but also to uncover whether alterations
in intestinal microbiota in the case of zonulin are the
consequences or the causes of autoimmune diseases.
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